[6-K] CyberArk Software Ltd. Current Report (Foreign Issuer)
CyberArk Software Ltd. (CYBR) filed a Form 6-K to disclose two key items. First, on 30 July 2025 the company and Palo Alto Networks, Inc. (PANW) signed a definitive Agreement and Plan of Merger under which PANW will acquire CyberArk. A joint press release (Ex. 99.1) and a webcast scheduled for 6:30 a.m. PT on the same day will provide further details. No purchase price, consideration mix or expected closing date is included in this filing.
Second, CyberArk furnished a press release (Ex. 99.2) titled “CyberArk Announces Strong Second Quarter 2025 Results.” While the filing incorporates the accompanying U.S.-GAAP balance sheet, income statement and cash-flow statement into various S-8 registration statements, the numerical results themselves are not presented in the body of the 6-K. Management characterises the quarter as “strong,” but specific revenue, EPS or guidance figures are unavailable here.
The filing clarifies that, except for the incorporated financial statements, the furnished information is not deemed “filed” under the Exchange Act, limiting liability exposure. CFO Erica Smith signed the report on 30 July 2025.
- Definitive merger agreement with Palo Alto Networks reduces execution uncertainty and positions shareholders for a liquidity event.
- Public characterisation of Q2 2025 as “strong” hints at continued operational momentum leading into the transaction.
- None.
Insights
TL;DR – PANW-CYBR definitive deal disclosed; financial terms absent.
The filing formally signals CyberArk’s agreement to be acquired by Palo Alto Networks, confirming earlier speculation of consolidation in identity security. Absence of deal economics prevents valuation work, but definitive status materially de-risks execution relative to an LOI. Webcast timing implies rapid investor communication. Incorporation of Q2 financial statements into S-8s suggests continuity of equity-compensation programs until close. Overall, the document is impactful because it moves CYBR’s standalone investment thesis to a take-out scenario, pending price details and regulatory approvals.